Liqun Zhang

St George's University Hospital NHS Foundation Trusts

Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.

Registry trials as an overall official

all conditions, ClinicalTrials.gov

NIH grants tied to them

1 more share only the name and are not shown

Trial papers

3416

PubMed author-name match

Trials

Studies that name Liqun Zhang as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:54 UTC. Open this list on ClinicalTrials.gov

Ph2
NCT05418010 · Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)
Queen Mary University of London · recruiting · Multiple Sclerosis, Clinically Isolated Syndrome of Demyelination · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 05:54 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

Most cited trial papers

Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:54 UTC. The ranking covers the 200 most relevant of 3416 PubMed records, and a shared surname and initials can bring in a namesake. All 3416 on PubMed